<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tiblj</journal-id><journal-title-group><journal-title xml:lang="ru">Туберкулез и болезни легких</journal-title><trans-title-group xml:lang="en"><trans-title>Tuberculosis and Lung Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-1230</issn><issn pub-type="epub">2542-1506</issn><publisher><publisher-name>Медицинские знания и технологии</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21292/2075-1230-2018-96-12-9-17</article-id><article-id custom-type="elpub" pub-id-type="custom">tiblj-1198</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ТУБЕРКУЛЕЗ, СОЧЕТАННЫЙ С ВИЧ-ИНФЕКЦИЕЙ, В РОССИИ: СТАТИСТИКА И ВЗАИМОСВЯЗИ</article-title><trans-title-group xml:lang="en"><trans-title>TUBERCULOSIS WITH CONCURRENT HIV INFECTION IN RUSSIA: STATISTICS AND CORRELATIONS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыбикова</surname><given-names>Э. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsybikova</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, главный научный сотрудник отдела анализа статистики здоровья населения</p><p>127254, Москва, ул. Добролюбова, д. 11.8 (495) 619-38-40.</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Chief Researcher of Department for Public Health Statistical Analysis11, Dobrolyubova St., Moscow, 127254+7 (495) 619-38-40.</p></bio><email xlink:type="simple">erzheny@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пунга</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Punga</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, главный научный сотрудник научно-организационного отдела</p><p>107564, Москва, Яузская аллея, д. 2.8 (499) 785-91-87.cniitramn@yandex.ru</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor, Chief Researcher of Research and Organizational Department</p><p>2, Yauzskaya Alleya, Moscow, 107564+7 (499) 785-91-87cniitramn@yandex.ru</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Русакова</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Rusakova</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, заведующая научно-организационным отделом.</p><p>107564, Москва, Яузская аллея, д. 2.8 (499) 785-91-87.cniitramn@yandex.ru</p></bio><bio xml:lang="en"><p>Doctor of Medical Sciences, Head of Research and Organizational Department</p><p>2, Yauzskaya Alleya, Moscow, 107564+7 (499) 785-91-87</p><p>cniitramn@yandex.ru</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Центральный НИИ организации и информатизации здравоохранения» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Institute for Health Organization and Informatics</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Центральный НИИ туберкулеза» РАН, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Tuberculosis Research Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>23</day><month>01</month><year>2019</year></pub-date><volume>96</volume><issue>12</issue><fpage>9</fpage><lpage>17</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Цыбикова Э.Б., Пунга В.В., Русакова Л.И., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Цыбикова Э.Б., Пунга В.В., Русакова Л.И.</copyright-holder><copyright-holder xml:lang="en">Tsybikova E.B., Punga V.V., Rusakova L.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tibl-journal.com/jour/article/view/1198">https://www.tibl-journal.com/jour/article/view/1198</self-uri><abstract><p>Цель исследования: анализ эпидемической ситуации по туберкулезу, сочетанному с ВИЧ-инфекцией (ТБ/ВИЧ-и), в субъектах РФ, определение взаимосвязанных эпидемиологических показателей.Материалы и методы. Использованы сведения из отчетных форм Росстата № 61, 8 и 33, а также данные Росстата о численности населения за 2017 г. Данные о структуре популяции пациентов с сочетанной патологией получены из отчетной формы Росстата № 61 за 2017 г. Для поиска взаимосвязей между показателями, характеризующими популяции пациентов с туберкулезом и пациентов с ТБ/ВИЧ-и, проведен корреляционный анализ (стандартные пакеты статистической программы Statistica).Результаты исследования. Распространение ТБ/ВИЧ-и в России характеризуется выраженной неравномерностью и наибольшей распространенностью в 35 субъектах РФ. Результаты корреляционного анализа показали, что в 37 субъектах РФ, где доля пациентов с ТБ/ВИЧ-и была низкой (&lt; 7% от общего числа пациентов с туберкулезом), смертность от туберкулеза в течение 1-го года наблюдения зависела от уровня распространения туберкулеза с множественной лекарственной устойчивостью возбудителя (МЛУ-ТБ) среди всех пациентов с туберкулезом. В 48 субъектах РФ, где доля пациентов с сочетанной патологией была высокой (≥ 7% от общего числа пациентов с туберкулезом), распространение МЛУ-ТБ и смертность среди пациентов с сочетанной патологией в течение 1-го года наблюдения напрямую зависели от уровня распространения сочетанной патологии. В 16 субъектах РФ, в которых доля впервые выявленных пациентов с сочетанной патологией с МЛУ-ТБ составляла от 23 до 60%, риск развития летальных исходов был наиболее высоким. Наличие сопутствующего гепатита установлено у 42% впервые выявленных пациентов с сочетанной патологией и у 43% ‒ в контингентах. </p></abstract><trans-abstract xml:lang="en"><p>The objective of the study is to analyze TB/HIV co-infection situation in the regions of RF and to identify correlated epidemiological rates.Subjects and methods. The data from Rosstat Forms no. 61, 8 and 33 were used as well as Rosstat data on the number of population for 2017.The data reflecting the structure of the patients with TB/HIV co-infection were obtained from Rosstat Form no. 61 for 2017.In order to define correlations between the rates characterizing the population of tuberculosis patients and patients with TB/HIV co-infection, the correlation analysis was performed (the standard tools of Statistica software).Results of the study. In Russia, TB/HIV co-infection was not equally prevalent and it was the highest in 35 regions of Russia. According to the results of correlation analysis, in 37 RF regions with a low level of TB/HIV co-infection (&lt; 7% of the total number of tuberculosis patients), tuberculosis mortality during the 1st year of follow-up depended on the prevalence of multiple drug resistant tuberculosis (MDR TB) among all tuberculosis patients. In 48 Russian regions with a high level of TB/HIV co-infection (≥ 7% of the total number of tuberculosis patients), the prevalence of MDR TB and mortality in the patients within the 1st year of follow up directly depended on the prevalence of this co-infection. In 16 Russian regions, where the portion of new cases with concurrent MDR TB made from 23 to 60%, the risk of lethal outcome was the highest. The co-morbidity with hepatitis was observed in 42% of new cases of co-infection and in 43% of all those being followed-up. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>туберкулез</kwd><kwd>сочетанный с ВИЧ-инфекцией</kwd><kwd>заболеваемость</kwd><kwd>МЛУ-ТБ</kwd><kwd>ШЛУ-ТБ</kwd><kwd>гепатит</kwd><kwd>смертность от туберкулеза</kwd><kwd>смертность от ВИЧ-инфекции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tuberculosis with concurrent HIV infection</kwd><kwd>incidence</kwd><kwd>MDR TB</kwd><kwd>XDR TB</kwd><kwd>hepatitis</kwd><kwd>tuberculosis mortality</kwd><kwd>HIV mortality</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Лечение туберкулеза: рекомендации. 4-е издание. – ВОЗ, Женева, 2011. – 183 с.</mixed-citation><mixed-citation xml:lang="en">Lecheniye tuberkuleza: rekomendatsii. [Guidelines for treatment of tuberculosis]. 4th revision, WHO, Geneva, 2011, 183 p.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Пунга В. В., Цыбикова Э. Б., Якимова М. А., Измайлова Т. В. Результаты лечения больных туберкулезом, сочетанным с ВИЧ-инфекцией. [Электронный научный журнал] // Социальные аспекты здоровья населения. ‒ 2017. № 1 (53). Режим доступа: http://vestnik.mednet. ru/content/category/5/90/30/lang,ru/</mixed-citation><mixed-citation xml:lang="en">Punga V.V., Tsybikova E.B., Yakimova M.А., Izmaylova T.V. Treatment outcomes for tuberculosis cases with concurrent HIV infection. Socialnye Aspekty Zdorovya Naseleniya, 2017, no. 1 (53), Epub., Available at: http://vestnik.mednet.ru/content/category/5/90/30/lang,ru/ (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Равильоне М. К., Коробицын А. А. Ликвидация туберкулеза – новая стратегия ВОЗ в эру целей устойчивого развития, вклад Российской Федерации // Туб. и болезни легких. ‒ 2016. ‒ Т. 94, № 11. ‒ С. 7-15.</mixed-citation><mixed-citation xml:lang="en">Raviglione M.K., Korobitsyn A.A. End TB – The new WHO strategy in the SDG era, and the contributions from the Russian Federation. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 11, pp. 7-15. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по лечению туберкулеза с множественной лекарственной устойчивостью. – Партнеры во имя здоровья, 2003. – 173 с.</mixed-citation><mixed-citation xml:lang="en">Rukovodstvo po lecheniyu tuberkuleza s mnozhestvennoy lekarstvennoy ustoychivostyu. [Guidelines on treatment of multiple drug resistant tuberculosis]. Partners in Health, 2003, 173 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Getahun H. et al. HIV infection associated tuberculosis: the epidemiology and the response // Clin. Infect. Dis. ‒ 2010. ‒ Vol. 50. ‒ Р. 201-207.</mixed-citation><mixed-citation xml:lang="en">Getahun H. et al. HIV infection associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis., 2010, vol. 50, pp. 201-207.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Goletti D., Weissman D., Jackson R. W. et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation // Immunol. ‒ 1996. ‒ Vol. 157, № 3. ‒ Р. 1271-1278.</mixed-citation><mixed-citation xml:lang="en">Goletti D., Weissman D., Jackson R.W. et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. Immunol., 1996, vol. 157, no. 3, pp. 1271-1278.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Guelar A., Gatell J. M., Verdejo J. et al. A prospective study of the risk of tuberculosis among HIV-infected patients // AIDS. ‒ 1993. ‒ Vol. 7, № 10. ‒ Р. 1345-1349.</mixed-citation><mixed-citation xml:lang="en">Guelar A., Gatell J.M., Verdejo J. et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS, 1993, vol. 7, no. 10, pp. 1345-1349.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sonnenberg P., Murray J., Glynn J. R. et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers // Lancet. ‒ 2001. ‒ Vol. 358 (9294). ‒ Р. 1687-1693.</mixed-citation><mixed-citation xml:lang="en">Sonnenberg P., Murray J., Glynn J.R. et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet, 2001, vol. 358 (9294), pp. 1687-1693.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tuberculosis surveillance and monitoring in Europe 2018. – WHO, 2018. – 141 pp. http://www.euro.who.int/__data/assets/pdf_file/0010/364663/tb-report-2018.pdf</mixed-citation><mixed-citation xml:lang="en">Tuberculosis surveillance and monitoring in Europe 2018. WHO, 2018, 141p. Available at: http://www.euro.who.int/__data/assets/pdf_file/0010/364663/tb-report-2018.pdf</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Waismann J. I., Palmero D. J., Albert F. A., Guemes Gurtubay J. L., Francos J. L., Negroni R. Improved prognosis in HIV/AIDS related multidrug resistant tuberculosis patients treated with highly active antiretroviral therapy // Medicina. ‒ 2001. ‒ Vol. 61, № 6. ‒ Р. 810-814.</mixed-citation><mixed-citation xml:lang="en">Waismann J.I., Palmero D.J., Albert F.A., Guemes Gurtubay J.L., Francos J.L., Negroni R. Improved prognosis in HIV/AIDS related multidrug resistant tuberculosis patients treated with highly active antiretroviral therapy. Medicina, 2001, vol. 61, no. 6, pp. 810-814.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Whalen C., Horsburgh C. R., Horn D., Lahart C., Simberkoff M., Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis // Am. J. Respir. Crit. Care Med. ‒ 1995. ‒ Vol. 151, № 1. ‒ Р. 129-135.</mixed-citation><mixed-citation xml:lang="en">Whalen C., Horsburgh C.R., Horn D., Lahart C., Simberkoff M., Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med., 1995, vol. 151, no. 1, pp. 129-135.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Three Is Meeting: Intensified case funding (ICF), Isoniazid preventive therapy (IPT) and TB Infection control (IC) for people living with HIV. Report of a joint WHO HIV/AIDS and TB department meeting. Geneva, WHO, 2008. http://who.int/hiv/pub/meeting-reports/WHO_3Is_meeting_report.pdf</mixed-citation><mixed-citation xml:lang="en">WHO Three Is Meeting: Intensified case funding (ICF), Isoniazid preventive therapy (IPT) and TB Infection control (IC) for people living with HIV. Report of a joint WHO HIV/AIDS and TB department meeting. Geneva, WHO, 2008. Available at: http://who.int/hiv/pub/meeting-reports/WHO_3Is_meeting_report.pdf</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
